Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One-Shot gene injection aims to restore sight in genetic blindness trial

NCT ID NCT07406854

Summary

This study is testing whether a single injection of an experimental gene therapy (NR082) into the eye is safe and can improve vision in people with Leber's hereditary optic neuropathy (LHON), a genetic condition that causes vision loss. The trial will enroll about 95 people aged 12 to 75 who have had vision loss for 6 months to 10 years due to a specific genetic mutation. Participants will be randomly assigned to receive either the real gene therapy injection or a sham (pretend) injection in both eyes to compare results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY (LHON) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Conditions

Explore the condition pages connected to this study.